People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endo, Inc. | — | Pharmaceuticals | Series D+ | $170.6M | $2.0B | 2024 |
Paul Herendeen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Herendeen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Barry | 1 | 4 |
| Mark Bradley | 1 | 3 |
| Paul Efron | 1 | 3 |
| Scott Hirsch | 1 | 2 |
| Matthew Maletta | 1 | 2 |
| Sophia Langlois | 1 | 1 |
| Frank Raciti | 1 | 1 |
| Andy Pasternak | 1 | 1 |
| Blaise Coleman | 1 | 1 |
| Marc Yoskowitz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.